Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.